PharmAI Discovery integrates deterministic AI, medicinal chemistry, and radiolabeling to convert challenging protein–protein interactions into first-in-class therapeutics and precision theranostics. Our end-to-end platform screens 300 M compounds, optimises leads, validates in vivo, and delivers IND-ready assets 18 months faster and with a 10× higher hit rate.